Design, synthesis, and biological activities of four angiotensin II receptor ligands with γ-turn mimetics replacing amino acid residues 3-5

Journal of Medicinal Chemistry

Volumn 40, Issue 6, 1997, Pages 903-919

  Schmidt, Boris ^a,d   Lindman, Susanna ^a   Tong, Weimin ^a   Lindeberg, Gunnar ^a   Gogoll, Adolf ^b   Lai, Zhennan ^b   Thörnwall, Madeleine ^b   Synnergren, Barbro ^b   Nilsson, Annika ^c   Welch, Christopher J ^a   Sohtell, Morgan ^c   Westerlund, Christer ^c   Nyberg, Fred ^b   Karlén, Anders ^a   Hallberg, Anders ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c ASTRAZENECA R AND D   (Sweden)

^d LEIBNIZ UNIVERSITY HANNOVER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II DERIVATIVE; ANGIOTENSIN RECEPTOR; DISULFIDE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; BLOOD PRESSURE REGULATION; CALCULATION; CYCLIZATION; DIASTEREOISOMER; DISULFIDE BOND; DRUG POTENCY; LIGAND BINDING; NUCLEAR MAGNETIC RESONANCE; PROTEIN CONFORMATION; STRUCTURE ACTIVITY RELATION;

EID: 15144349952     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm960553d     Document Type: Article

References (68)

1. Hruby, V. J. Conformational Restriction of Biologically Active Peptides via Amino Acid Side Chain Groups. Life Sci. 1982, 31, 189-199.
2. Regoli, D.; Park, W. K.; Rioux, F. Pharmacology of Angiotensin. Pharmacol. Rev. 1974, 26, 69-123.
3. Moore, G. J. Angiotensin and Bradykinin Receptors. Membranes and Receptors; Pergamon Press: Oxford, 1990; Vol. III, pp 961-980.
4. Hodges, J. C.; Hamby, J. M.; Blankley, C. J. Angiotensin II Receptor Binding Inhibitors. Drugs Future 1992, 17, 575-593.
5. Nikiforovich, G. V.; Marshall, G. R. Three-Dimensional Recognition Requirements for Angiotensin Agonists: A Novel Solution for an Old Problem. Biochem. Biophys. Res. Commun. 1993, 195, 222-228.
6. Nikiforovich, G. V.; Kao, J. L.-F.; Plucinska, K.; Zhang, W. J.; Marshall, G. R. Conformational Analysis of Two Cyclic Analogs of Angiotensin: Implication for the Biologically Active Conformation. Biochemistry 1994, 33, 3591-3598.
7. Joseph, M.-P.; Maigret, B.; Scheraga, H. A. Proposals for the Angiotensin II Receptor-Bound Conformation by Comparative Computer Modeling of AII and Cyclic Analogs. Int. J. Pept. Protein Res. 1995, 46, 514-526.
8. Samanen, J. M.; Peishoff, C. E.; Keenan, R. M.; Weinstock, J. Refinement of a Molecular Model of Angiotensin II (AII) Employed in the Discovery of Potent Nonpeptide Antagonists. Bioorg. Med. Chern. Lett. 1993, 3, 909-914.
9. Spear, K. L.; Brown, M. S.; Reinhard, E. J.; McMahon, E. G.; Olins, G. M.; Palomo, M. A.; Patton, D. R. Conformational Restriction of Angiotensin II: Cyclic Analogues Having High Potency. J. Med. Chem. 1990, 33, 1935-1940.
10. 8]-angiotensin II. In Peptides: Chemistry, Structure and Biology: Proceedings of the Eleventh American Peptide Symposium; Rivier, J. E., Marshall, G. R., Eds.; ESCOM Publishers: Leiden, 1990; pp 305-306.
11. To further evaluate compounds 2 and 3, we studied their antagonistic activity in two pharmacological in vivo models (for experimental details, see Supporting Information). The first model investigated the antihypertensive response in conscious spontaneously hypertensive rats (SHR), using DuP 753 (losartan) as a reference compound. Compound 2 displayed weak antihypertensive effects compared to DuP 753. Compound 3, however, showed a pronounced hypotensive effect even at very low concentrations (0.001 μmol/kg). Higher concentrations than 0.1 μmol/kg compound 3 could not be given due to adverse cardiac effects. These effects did not seem to be related to parasympatic activity as similar results were obtained in rats pretreated with atropine. In the second model, SHR were constantly infused with Ang I. No dose dependent hypotensive effect was seen for compound 2 or 3, even at a dose of 10 μmol/ kg compound 2 and 1 μmol/kg compound 3. DuP 753 investigated in the latter in vivo model showed a dose dependent hypotensive effect on the mean arterial blood pressure. The antagonistic/ hypotensive effect that compound 3 displays in one of the in vivo models could be argued as being an effect on the renin angiotensin system as compound 3 did not show any dose dependent hypotensive effect during Ang I infusion. This would rather support the agonistic profile seen in the rabbit aorta strips model.
12. Maehr, H. A Proposed New Convention for Graphic Presentation of Molecular Geometry and Topography. J. Chem. Educ 1985, 62, 114-120.
13. Kataoka, T.; Beusen, D. D.; Clark, J. D.; Yodo, M.; Marshall, G. R. The Utility of Side-Chain Cyclization in Determining the Receptor-Bound Conformation of Peptides: Cyclic Tripeptides and Angiotensin II. Biopolymers 1992, 32, 1519-1533.
14. Pramanik, B.; Tsarbopoulos, A.; Labdon, J. E.; Czarniecki, M.; Nagabhushan, T. L.; Trotta, P. P. Demonstration of a 1-3 Disulfide Bond in a Synthetic Nonapeptide Derived from the Signal Sequence and N-Terminus of Human γ-Interferon. Biochem. Biophys. Res. Commun. 1988, 157, 836-843.
15. Kishore, R.; Balaram, P. Stabilization of γ-turn Conformations in Peptides by Disulfide Bridging. Biopolymers 1985, 24, 2041-2043.
16. Still, W. C.; Tempczyk, A.; Hawley, R. C.; Hendrickson, T. Semianalytical Treatment of Solvation for Molecular Mechanics and Dynamics. J. Am. Chem. Soc. 1990, 112, 6127-6129.
17. Mohamadi, F.; Richards, N. G. J.; Guida, W. C.; Liskamp, R.; Lipton, M.; Caufield, C.; Chang, G.; Hendrickson, T.; Still, W. C. MacroModel - An Integrated Software System for Modeling Organic and Bioorganic Molecules Using Molecular Mechanics. J. Comput. Chem. 1990, 11, 440-467.
18. i+2 angles of β-turns are as follows: type I, -60°, -30°, -90°, 0°; type II, -60°, 120°, 80°, 0°; type III, -60°, -30°, -60°, -30°; type I′, 60°, 30°, 90°, 0°; etc.; see: Smith, J. A.; Pease, L. G. Reverse Turns in Peptides and Proteins. CRC Crit. Rev. Biochem. 1980, 8, 315-399.
19. Schenkin, P. S.; McDonald, D. Q. Cluster Analysis of Molecular Conformations. J. Comput. Chem. 1994, 15, 899-916.
20. Lewis, P. N.; Momany, F. A.; Scheraga, H. A. Chain Reversals in Proteins. Biochim. Biophys. Acta 1973, 305, 211-229.
21. Dyson, H. J.; Rance, M.; Houghten, R. A.; Lerner, R. A.; Wright, P. E. Folding of Immunogenic Peptide Fragments of Proteins in Water Solution. J. Mol. Biol. 1988, 207, 161-200.
22. Sybyl: Molecular Modeling System. Tripos Associates, Inc., St. Louis, MO.
23. In Sybyl, hydrogen bonds are identified if the minimum and maximum distance between a hydrogen bonded to a H-bond donor and acceptor is between 0.8 and 2.8 Å. Another restriction is that the angle formed by the donor, the hydrogen, and the acceptor atoms must be larger than 120°.
24. Ludvigsen, S.; Andersen, K. V.; Poulsen, F. M. Accurate Measurements of Coupling Constants from Two-Dimensional Nuclear Magnetic Resonance Spectra of Proteins and Determinations of Φ-Angles. J. Mol. Biol. 1991, 217, 731-736.
25. Huffman, W. F.; Callahan, J. F.; Eggleston, D. S.; Newlander, K. A.; Takata, D. T.; Codd, E. E.; Walker, R. F.; Schiller, P. W.; Lemieux, C.; Wire, W. S.; Burks, T. F. Reverse Turn Mimics. In Peptides: Chemistry and Biology: Proceedings of the Tenth American Peptide Symposium: Marshall, G. R., Ed.; ESCOM Publishers: Leiden, 1988; pp 105-108.
26. Callahan, J. F.; Newlander, K. A.; Burgess, J. L.; Eggleston, D. S.; Nichols, A.; Wong, A.; Huffman, W. F. The Use of γ-Turn Mimetics to Define Peptide Secondary Structure. Tetrahedron 1993, 49, 3479-3488.
27. Sato, M.; Lee, J. Y. H.; Nakanishi, H.; Johnson, M. E.; Chrusciel, R. A.; Kahn, M. Design, Synthesis and Conformational Analysis of γ-Turn Peptide Mimetics of Bradykinin. Biochem. Biophys. Res. Commun. 1992, 187, 999-1006.
28. Huffman, W. F.; Callahan, J. F.; Codd, E. E.; Eggleston, D. S.; Lemieux, C.; Newlander, K. A.; Schiller, P. W.; Takata, D. T.; Walker, R. F. Mimics of Secondary Structural Elements of Peptides and Proteins. In Synthetic Peptides: Approaches to Biological Problems; Tam, J. P., Kaiser, E. T., Eds.; A. R. Liss: New York, 1989; Vol. 86, pp 257-266.
29. 7 mimetic for the Predicted γ-Turn Conformation Found in Several Constrained RGD Antagonists J. Med. Chem. 1992, 35, 3970-3972.
30. Newlander, K, A.; Callahan, J. F.; Moore, M. L.; Tomaszek, T. A.; Huffman, W. F. A Novel Constrained Reduced-Amide Inhibitor of HIV-1 protease Derived from the Sequential Incorporation of γ-Turn Mimetics into a Model Substrate. J. Med. Chem. 1993, 36, 2321-2331.
31. Marshall, G. R. Definition of the Receptor-Bound Conformation of Angiotensin II. Dtsch. Apoth. Ztg. 1986, 126, 2783-2786.
32. Duncia, J. V.; Chiu, A. T.; Carini, D. J.; Gregory, G. B.; Johnson, A. L.; Price, W. A.; Wells, G. J.; Wong, P. C.; Calabrese, J. C.; Timmermans, P. B. M. W. M. The Discovery of Potent Nonpeptide Angiotensin II Receptor Antagonists: A New Class of Potent Antihypertensives. J. Med. Chem. 1990, 33, 1312-1329.
33. Weinstock, J.; Keenan, R. M.; Samanen, J.; Hempel, J.; Finkelstein, J. A.; Franz, R. G.; Gaitanopoulos, D. E.; Girard, G. R.; Gleason, J. G.; Hill, D. T.; Morgan, T. M.; Peishoff, C. E.; Aiyar, N.; Brooks, D. P.; Fredrickson, T. A.; Ohlstein, E. H.; Ruffolo, R. R., Jr.; Stack, E. J.; Sulpizio, A. C.; Weidley, E. F.; Edwards, R. M. 1-(Carboxybenzyl)imidazole-5-acrylic Acids: Potent and Selective Angiotensin II Receptor Antagonists. J. Med. Chem. 1991, 34, 1514-1517.
34. Iio, H.; Isobe, M.; Kawai, T.; Goto, T. Total Synthesis of Vernolepin. I. Synthesis of the Key Intermediate. Tetrahedron 1979, 35, 941-948.
35. Hanessian, S.; Lavallee, P. The Preparation and Synthetic Utility of tert-Butyldiphenylsilyl Ethers. Can. J. Chem. 1975, 53, 2975-2977.
36. 18 Cecropia Juvenile Hormone. J. Am. Chem. Soc. 1968, 90, 5618-5620.
37. Pappas, J. J.; Keaveney, W. P.; Gancher, E.; Berger, M. A New and Convenient Method for Converting Olefins to Aldehydes. Tetrahedron Lett. 1966, 7, 4273-4278.
38. Borch, R. F.; Bernstein, M. D.; Durst, H. D. The Cyanohydridoborate Anion as a Selective Reducing Agent. J. Am. Chem Soc. 1971, 93, 2897-2904.
39. Shioiri, T.; Ninomiya, K.; Yamada, S. Diphenylphosphoryl Azide. A New Convenient Reagent for a Modified Curtius Reaction and for the Peptide Synthesis. J. Am. Chem. Soc. 1972, 94, 6203-6205.
40. Roush, W. R.; Straub, J. A.; Brown, R. J. Stereochemistry of the Epoxidations of Acyclic Allylic Amides. Applications Toward the Synthesis of 2,3,6-Trideoxy-3-aminohexoses J. Org. Chem. 1987, 52, 5127-5136.
41. G-2,2,5,7,8-Pentamethylchroman-6-sulphonyl-L-arginine. Tetrahedron 1991, 47, 6353-6370.
42. Tam, J. P.; Merrifield, R. B. Strong Acid Deprotection of Synthetic Peptides: Mechanisms and Methods. In The Peptides: Analysis, Synthesis, Biology. Special Methods in Peptide Synthesis, Part C; Udenfriend, S., Meienhofer, J., Eds.; Academic Press: San Diego, 1987; Vol. 9, pp 185-248.
43. Anwer, M. K.; Porter, R. A.; Spatola, A. F. Applications of Ammonium Formate-Catalytic Transfer Hydrogenation. Int. J. Pept. Protein Res. 1987, 30, 489-497.
44. Sivanandaiah, K. M.; Gurusiddappa, S. Catalytic Transfer Hydrogénation of Protected Peptides at Room Temperature. J. Chem. Res., Synop. 1979, 108-109.
45. Crivello, J. V. Nitrations and Oxidations with Inorganic Nitrate Salts in Trifluoroacetic Anhydride. J. Org. Chem. 1981, 46, 3056-3060.
46. Philippe, N.; Levacher, V.; Dupas, G.; Duflos, J.; Quéguiner, G.; Bourguignon, J. Diastereoselective Alkylation of Homochiral 1,2,3,4-Tetrahydroisoquinolin-3-one. A Potential Route to Enantiomerically Pure 4-Substituted Tetrahydroisoquinolines. Tetrahedron: Asymmetry 1996, 7, 417-420.
47. Lan, A. J. Y.; Heuckeroth, R. O.; Mariano, P. S. Electron-Transfer-Induced Photocyclization Reactions of Arene-Iminium Salt Systems. Effects of Cation Diradical Deprotonation and Desilylation on the Nature and Efficiencies of Reaction Pathways Followed. J. Am. Chem. Soc. 1987, 109, 2738-2745.
48. Ram, S.; Ehrenkaufer, R. E. A General Procedure for Mild and Rapid Reduction of Aliphatic and Aromatic Nitro Compunds Using Ammonium Formate as a Catalytic Hydrogen Transfer Agent. Tetrahedron Lett. 1984, 25, 3415-3418.
49. Chiu, A. T.; Carini, D. J.; Duncia, J. V.; Leung, K. H.; McCall, D. E.; Price, W. A., Jr.; Wong, P. C.; Smith, R. D.; Wexler, R. R.; Timmermans, P. B. M. W. M.; Chang, R. S. L.; Lotti, V. J. DuP 532: A Second Generation of Nonpeptide Angiotensin II Receptor Antagonists. Biochem. Biophys. Res. Commun. 1991, 177, 209-217.
50. Kim, K. S.; Qian, L.; Bird, J. E.; Dickinson, K. E. J.; Moreland, S.; Schaeffer, T. R.; Waldron, T. L.; Delaney, C. L.; Weller, H. N.; Miller, A. V. Quinoxaline N-Oxide Containing Potent Angiotensin II Receptor Antagonists: Synthesis, Biological Properties, and Structure-Activity Relationships. J. Med. Chem 1993, 36, 2335-2342.
51. Whitebread, S.; Mele, M.; Kamber, B.; de Gasparo, M. Preliminary Biochemical Characterization of Two Angiotensin II Receptor Subtypes. Biochem. Biophys. Res. Commun. 1989, 163, 284-291.
52. 63.
53. Scanlon, M. N.; Matsoukas, J. M.; Franklin, K. J.; Moore, G. J. A New Approach to Angiotensin Antagonists: Methylation of the Tyrosine Hydroxyl in Angiotensin II. Life Sci. 1984, 34, 317-321.
54. Joseph, M.-P.; Maigret, B.; Bonnafous, J.-C.; Marie, J.; Scheraga, H. A. A Computer Modeling Postulated Mechanism for Angiotensin II Receptor Activation. J. Protein Chem. 1995, 14, 381-398.
55. Printz, M. P.; Nemethy, G.; Bleich, H. Proposed Models for Angiotensin II in Aqueous Solution and Conclusion about Receptor Topography. Nature (London), New Biol. 1972, 237, 135-140.
56. Khosla, M. C.; Smeby, R. R.; Bumpus, F. M. Structure Activity Relationship in Angiotensin II Analogs. In Handbook of Experimental Pharmacology; Page, I. H., Bumpus, F. M., Eds.; Springer Verlag: New York, 1974; Vol. 37, pp 126-161.
57. Jorgensen, E. C.; Rapaka, S. R.; Windridge, G. C.; Lee, T. C. Angiotensin II Analogs. 7. Stereochemical Factors in the 5 Position Influencing Pressor Activity. 2. J. Med. Chem. 1971, 14, 904-906.
58. Samanen, J.; Cash, T.; Narindray, D.; Brandeis, E.; Adams, W., Jr.; Weideman, H.; Yellin, T. An Investigation of Angiotensin II Agonist and Antagonist Analogues with 5,5-Dimethylthiazolidine-4-carboxylic Acid and Other Constrained Amino Acids. J. Med. Chem. 1991, 34, 3036-3043.
59. Plucinska, K.; Kataoka, T.; Yodo, M.; Cody, W. L.; He, J. X.; Humblet, C.; Lu, G. H.; Lunney, E.; Major, T. C.; Panek, R. L.; Schelkun, P.; Skeean, R.; Marshall, G. R. Multiple Binding Modes for the Receptor-Bound Conformations of Cyclic AII Agonists. J. Med. Chem. 1993, 36, 1902-1913.
60. Barlos, K.; Gatos, D.; Kallitsis, J.; Papaphotiu, G.; Sotiriu, P.; Wenqing, Y.; Schäfer, W. Darstellung Geschützter Peptid-Fragmente unter Einsatz Substituierter Triphenylmethyl-Harze. (Preparation of protected peptide fragments using triphenylmethyl resins.) Tetrahedron Lett. 1989, 30, 3943-3946.
61. Cottet, F.; Cottier, L.; Descotes, G. New Syntheses of Isochromene. Synthesis 1987, 497.
62. Spangler, R. J.; Kim, J. H. The Pyrolysis of Isochroman-3-one. A Convenient Synthesis of Benzocyclobutene. Synthesis 1973, 107-108.
63. Lai, Z.; Zhai, Q.; Yukhananov, R.; Larsson, C.; Roos, P.; Kreek, M. J.; Nyberg, F. Effects of Morphine on Prolactin Receptors in the Rat Brain. FEBS Lett. 1994, 338, 207-211.
64. Piantini, U.; Sørensen, O. W.; Ernst, R. R. Multiple Quantum Filters for Elucidating NMR Coupling Networks. J. Am. Chem. Soc. 1982, 104, 6800-6801.
65. Bothner-By, A. A.; Stephens, R. L.; Lee, J.; Warren, C. D.; Jeanloz, R. W. Structure Determination of a Tetrasaccharide: Transient Nuclear Overhauser Effects in the Rotating Frame. J. Am. Chem. Soc. 1984, 106, 811-813.
66. States, D. J.; Haberkorn, R. A.; Ruben, D. J. A Two-Dimensional Nuclear Overhauser Experiment with Pure Absorption Phase in Four Quadrants. J. Magn. Reson. 1983, 48, 286-292.
67. 1H NMR of Proteins. Experimental Procedures. J. Magn. Reson. 1984, 56, 207-234.
68. Goodman, J. M.; Still, W. C. An Unbounded Systematic Search of Conformational Space. J. Comput. Chem. 1991, 12, 1110-1117.